Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

GeNeuro

GeNeuro
2006 FOUNDED
PUBLIC STATUS
21-30 EMPLOYEES
GNRO STOCK SYMBOL
$3.75 SHARE PRICE (As of Monday Closing)
Description

GeNeuro SA is a clinical-stage biopharmaceutical company. The company is developing a new approach to the treatment of autoimmune diseases, including multiple sclerosis and other diseases associated with human endogenous retroviruses (HERV). Its lead therapeutic candidate is GNbAC1 which is a humanized monoclonal antibody that neutralizes a pathogenic HERV protein of the W family called pHERV-W env (also called MSRV env) that has been identified as a potential key factor in the onset and development of autoimmune diseases. Geographically, the group holds a presence in the region of France and Switzerland.

Website
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Stock Exchange
PAR
Primary Office
  • 18, chemin des Aulx
  • Plan-les-Ouates
  • CH-1228 Geneva
  • Switzerland

+41 022 000 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore GeNeuro’s full profile, request a free trial.

GeNeuro Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$2.96 - $5.61 $54.6M $3.74 -$0.82 1.58K 14.6M

GeNeuro Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 53,236 37,698 73,654 110,932
Revenue 131 8,807 16,859 6,546
EBITDA (11,696) (9,746) (6,501) (15,566)
Net Income (11,931) (9,827) (6,583) (15,600)
Total Assets 16,178 16,074 36,434 39,734
Total Debt 9,401
Public Fundamental Data provided by Morningstar, Inc. disclaimer

GeNeuro Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore GeNeuro‘s full profile, request access.

Request full access to PitchBook

GeNeuro Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore GeNeuro‘s full profile, request access.

Request full access to PitchBook

GeNeuro Executive Team (6)

Name Title Board
Seat
Contact
Info
Miguel Payró Chief Financial Officer
Francois Curtin MD Chief Operating Officer
Alois Lang Ph.D Chief Development Officer
Herve Perron Ph.D Founder & Chief Scientific Officer
Robert Glanzman Chief Medical Officer
You’re viewing 5 of 6 executives. Get the full list »